Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012
Brief Summary: RATIONAL: Preliminary results fron the Study MESOT-TREM-2012 indicate a promising activity of tremelimumab in malignant mesothelioma (MM) patients.

PURPOSE: The proposed study MESOT-TREM-2012 aims to explore the efficacy of a more intensive schedule of treatment with tremelimumab in 29 MM patients. Subjects will receive investigational product every 4 weeks (wks) for 6 doses, followed by doses every 12 wks until confirmed disease progression.


Options:
A: Arm Label: Regimen A; Type: EXPERIMENTAL; Interventions: Biological: filgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: vincristine sulfate, Procedure: adjuvant therapy, Procedure: conventional surgery, Procedure: neoadjuvant therapy, Radiation: brachytherapy, Radiation: radiation therapy | Arm Label: Regimen B; Type: EXPERIMENTAL; Interventions: Biological: filgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: vincristine sulfate, Procedure: adjuvant therapy, Procedure: conventional surgery, Procedure: neoadjuvant therapy, Radiation: brachytherapy, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: RADIATION; Name: brachytherapy; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Regimen A, Regimen B
B: Arm Label: gemcitabine/docetaxel then doxorubicin; Type: OTHER; Interventions: Drug: gemcitabine, docetaxel, doxorubicin | Intervention Type: DRUG; Name: gemcitabine, docetaxel, doxorubicin; Assigned to Arm(s): gemcitabine/docetaxel then doxorubicin
C: Arm Label: single arm with Tremelimumab; Type: EXPERIMENTAL; Interventions: Drug: Tremelimumab | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): single arm with Tremelimumab
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Eribulin mesylate 1.4 mg/m^2 intravenous | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV | Intervention Type: DRUG; Name: Eribulin mesylate 1.4 mg/m^2 intravenous; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV; Assigned to Arm(s): Arm B

Answer: C